Q-omics provides the consensus-scored BLNK profile across patient tissues and cancer cell-line models. BLNK expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, BLNK is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, BLNK protein abundance shows 18,100 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight BLCA, KIRC, and LSCC as cancer lineages where BLNK shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BLNK — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BLNK survival associations across molecular data types. BLNK RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BLNK RNA expression–survival associations across cancer types. High BLNK expression shows unfavorable associations in KIRP and LGG, but favorable associations in BLCA, SKCM, HNSC and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for BLNK RNA expression.
This table summarizes BLNK tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for BLNK. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BLNK shows lower tumor expression in KIRC, HNSC, KIRP and COAD and higher tumor expression in THCA and BRCA. The KIRC box plot shows higher BLNK RNA expression in normal versus tumor tissue (log2 FC = −1.246, t-test p < 0.001).
This table shows molecular features associated with BLNK in patient tissues and cancer cell lines. In patient samples, BLNK shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, BLNK RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BLOOD_Lymphoma.
